Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said Tuesday in its quarterly report. Merck, which is facing plummeting sales ...

There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing ...

After recently placing a spotlight on Novo Nordisk’s "outrageous" U.S. | A new Senate HELP Committee report says GLP-1 drugs could "bankrupt our entire health care system" because of their high ...

This week on "The Top Line," we bring you a special conversation from our New York City gala, where we celebrated this year’s Fierce 50 honorees.

Awaiting a Medicare coverage decision on its controversial Alzheimer’s drug, Biogen is making an unexpected goodwill gesture—and initiating an expected restructuring—as it faces pressure ...

After years of navigating regulatory woes and financial troubles, Akorn Pharmaceuticals is calling it quits. | It's the end of a rocky road for Akorn. After years of financial problems, the ...

It’s official—the first FDA approved CBD product is on the market. | The first FDA-approved CBD product hit shelves Thursday with GW Pharmaceuticals' cannabinoid Epidiolex, approved to treat ...

Novo Nordisk will spend $4.1B to construct a second fill-finish plant at its sprawling campus in Clayton, North Carolina, where it makes Ozempic and Wegovy.

The landmark FDA approval makes Enhertu the first therapy targeted to treat unresectable or metastatic breast cancer expressing low levels of HER2.

After much anticipation and concern, the BIOSECURE Act—which would prevent U.S. companies from working with certain Chinese biotech service providers—has passed a key threshold.

For the first time, an HIV PrEP drug candidate has shown zero infections in a phase 3 trial. The result came from the PURPOSE 1 trial evaluating Gilead Sciences’ twice-yearly, subcutaneous ...

Teva has been working to address shortfalls at a manufacturing site in California for years, but a recent layoff notice indicates those efforts are winding down. | Teva Parenteral Medicines is ...